Table 2. Risk factors associated with acquired hypofibrinogenemia in both models.

Variables	Model 1a						Model 2b
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	OR (95% CI)	P		OR (95% CI)	P		OR (95% CI)	P		OR (95% CI)	P
Age	1.016 (0.994–1.038)	0.153		1.025 (1.000–1.051)	0.043		1.016 (0.994–1.038)	0.153		1.026 (1.001–1.051)	0.043
Men	2.652 (1.425–4.937)	0.002		3.277 (1.633–6.579)	0.001		2.652 (1.425–4.937)	0.002		2.329 (1.095–4.956)	0.028
Current smoker	0.330 (0.090–1.212)	0.095					0.330 (0.090–1.212)	0.095
Pack-years	0.967 (0.944–0.991)	0.008					0.967 (0.944–0.991)	0.008
DIC	0.453 (0.074–2.778)	0.392					0.453 (0.074–2.778)	0.392
Massive hemoptysis	1.867 (0.975–3.577)	0.060					1.867 (0.975–3.577)	0.060
Baseline fibrinogen	0.996 (0.994–0.998)	<0.000		0.996 (0.994–0.999)	0.002		0.996 (0.994–0.998)	<0.000		0.996 (0.994–0.999)	0.001
Platelet	0.998 (0.995–1.001)	0.153					0.998 (0.995–1.001)	0.153
PT (INR)	0.575 (0.221–1.496)	0.257					0.575 (0.221–1.496)	0.257
aPTT	0.961 (0.906–1.018)	0.177					0.961 (0.906–1.018)	0.177
Duration of batroxobin use	1.201 (1.015–1.421)	0.033		1.244 (1.019–1.519)	0.032
Total doses of batroxobin							1.012 (1.000–1.024)	0.057		1.014 (1.000–1.029)	0.049

^a, model 1 include duration of batroxobin use; ^b, model 2 include total doses of batroxobin. OR, odds ratio; CI, confidence interval; DIC, disseminated intravascular coagulation; PT, prothrombin time; INR, international normalized ratio.